anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor nilotinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer. In particular, the present disclosure provides a pharmaceutical composition in the form of an orally disintegrating tablet. In some embodiments, the pharmaceutical compositions can be administered without regard to food consumption. In other embodiments, the pharmaceutical compositions can be administered at a significantly lower dose as compared to a commercially available immediate-release nilotinib formulation, while providing a comparable therapeutic effect. The disclosure further provides a discriminating in vitro dissolution characterization method.
Platelet-derived growth factors (PDGFs) and receptors (PDGFR) play a key role in the process of coronary atherosclerosis. We aimed to investigate the association of genetic variations and mRNA expressions of PDGF/PDGFRB pathway genes with coronary artery disease (CAD). In this case-control study (3139 CAD vs. 3270 controls), 13 single nucleotide polymorphisms (SNPs) at five pathway genes were genotyped and combined to construct a weighted genetic risk score (wGRS). Three hundred and six pairs of cases and controls were selected for mRNA quantification. Restricted cubic spline (RCS) analyses were conducted for the dose-response relationship between wGRS, mRNAs and CAD. Area under the curve (AUC) was estimated to evaluate the discrimination of wGRS, mRNAs, and traditional risk factors (TRF) for CAD. The wGRS exhibited a positive linear relationship with CAD (p for linearity <0.001), and the medium and high wGRS had 37% and 50% increased risk of CAD compared to the low wGRS group (p = 1.5 × 10-4; p = 5.7 × 10-5). mRNA expression levels of five genes in peripheral blood leukocytes were all lower among patients at admission than controls (p < 0.001). The PDGF/PDGFRB mRNA expressions had significant non-linear correlations with AMI, with "U"-shaped trend for PDGFA, PDGFB and "L"-shaped trend for PDGFC, PDGFD and PDGFRB. Adding wGRS and mRNAs to the TRF model significantly improved the discrimination for CAD with an AUC of 0.921 (95% CI, 0.898-0.943). Genetic variations in the PDGF/PDGFRB pathway contribute to CAD susceptibility with a significantly joint effect. The down-regulated PDGF/PDGFRB mRNAs in peripheral leukocytes have the potential as blood-based biomarkers for CAD with high discriminative value.
BACKGROUND AND PURPOSE: Cementless arthroplasty fixation relies on early bone ingrowth and may be poor in patients with low proximal tibial bone density or abnormal bone turnover. We aimed first to describe the baseline bone properties in patients undergoing medial unicompartmental knee replacement (UKR), and second to investigate its association with cemented and cementless tibial component migration until 2 years.
METHODS: A subset investigation of 2 patient groups from a 3-armed randomized controlled trial was conducted. There were 26 cemented and 25 cementless medial UKRs with twin-pegged femoral components. Volumetric bone mineral density (vBMD) and microstructure of the excised medial tibial plateau were ascertained with µCT. Bone turnover was estimated using dynamic histomorphometry (eroded surface/bone surface = ES/BS, osteoid surface/bone surface = OS/BS, mineralizing surface/bone surface = MS/BS). Tibial component migration in 4 feature points was followed for 2 years with radiostereometry.
RESULTS: At the 2-year follow-up, the cementless tibial components migrated 0.38 mm (95% confidence interval [CI] 0.14-0.62) total translation more than the cemented components at the posterior feature point. The greatest migration in the cementless group was subsidence at the posterior feature point of 0.66 mm (CI 0.48-0.84) until 6 weeks, and from 3 months the components were stable. Cemented tibial components subsided very little. Between 1- and 2-year follow-ups, no cementless but 4 cemented tibial components revealed continuous migration. OS/BS was half of the ES/BS. No µCT or histomorphometric parameters showed any clinically relevant correlation with tibial component migration at the posterior feature point for either cemented or cementless UKR at 6 weeks' or 2 years' follow-up after adjustment for age, BMI, and sex.
CONCLUSION: Preoperative vBMD, bone turnover, and microstructure were not associated with postoperative tibial component migration of cemented and cementless medial UKR.
Angioedema: Angioedema, including laryngeal edema, can occur with treatment with ACE inhibitors, especially following the first dose. Patients should be advised to immediately report to their physician any signs or symptoms suggesting angioedema (e.g., swelling of face, eyes, lips, tongue, larynx, mucous membranes, and extremities; difficulty in swallowing or breathing; hoarseness) and to discontinue therapy. (See WARNINGS: Head and Neck Angioedema and ADVERSE REACTIONS.)

Symptomatic Hypotension: Patients should be cautioned that lightheadedness can occur, especially during the first days of therapy, and it should be reported to a physician. Patients should be told that if syncope occurs, fosinopril sodium should be discontinued until the physician has been consulted. All patients should be cautioned that inadequate fluid intake or excessive perspiration, diarrhea, or vomiting can lead to an excessive fall in blood pressure, with the same consequences of lightheadedness and possible syncope.

Hyperkalemia: Patients should be told not to use potassium supplements or salt substitutes containing potassium without consulting the physician.

Neutropenia: Patients should be told to promptly report any indication of infection (e.g., sore throat, fever), which could be a sign of neutropenia.

Pregnancy: Female patients of childbearing age should be told about the consequences of second-and third-trimester exposure to ACE inhibitors, and they should also be told that these consequences do not appear to have resulted from intrauterine ACE-inhibitor exposure that has been limited to the first trimester. These patients should be asked to report pregnancies to their physician as soon as possible.
Hepatocellular carcinoma (HCC) hematogenous dissemination is a leading cause of HCC-related deaths. The inflammatory facilitates this process by promoting the adhesion and invasion of tumor cells in the circulatory system. But the contribution of hemodynamics to this process remains poorly understood due to the lack of a suitable vascular flow model for investigation. This study develops a vascular flow model to examine the impact of hemodynamics on endothelial inflammation-mediated HCC metastasis. This work finds the increasing shear stress will reduce the recruitment of HCC cells by disturbing adhesion forces between endothelium and HCC cells. However, this reduction will be restored by the inflammation. When applying high FSS (4-6 dyn cm-2) to the inflammatory endothelium, there will be a 4.8-fold increase in HCC cell adhesions compared to normal condition. Nevertheless, the increase fold of cell adhesions is inapparent, around 1.5-fold, with low and medium FSS. This effect can be attributed to the FSS-induced upregulation of ICAM-1 and VCAM-1 of the inflammatory endothelium, which serve to strengthen cell binding forces. These findings indicate that hemodynamics plays a key role in HCC metastasis during endothelial inflammation by regulating the expression of adhesion-related factors.
Hard paper copy of as well as an electronic copy of the guide will be provided to subjects and study staff will provide a general review of the contents of the guide with subjects during their education sessions. Participants will be in this group for 6 months.
Example embodiments relate to a system for monitoring biosignals. Example embodiments also relate to a patch and an apparatus which may comprise part of the system. For example, the system may comprise a patch comprising a surface for attachment to a user, one or more first sensors for sensing respective first biosignals of the user, and a transmitter for wirelessly transmitting first biosignal data representing the first biosignals of the user. The system may also comprise an apparatus for being worn or placed over the patch, the apparatus comprising one or more second sensors at or near a lower surface thereof for sensing respective second biosignals of the user and providing second biosignal data representing the second biosignals. The apparatus may also comprise a receiver for wirelessly receiving the first biosignal data from the patch. The patch may comprise one or more recesses or apertures for alignment with the one or more second sensors when the apparatus is worn or placed over the patch.
PURPOSE: To enable the stabilization of vitamin B1 preparation unstable in a solution. CONSTITUTION: A liquid preparation containing vitamin B1 is compounded with a fat in form of a fat emulsion having an average particle diameter of <=0.17μm. The compounding ratio of the fat is >=10 times, preferably 1,500-15,000 times vitamin B1 (in weight). When the fat is added at the ratio of 3,000-10,000 times, the fat in the obtained liquid preparation containing vitamin B1 works as a nutritional supplement besides the stabilization of vitamin B1, and the agent performs a vitamin B1 supplement and a nutrition supplement at the same time in a good balance. Such preparation is also stable. Further, in the case where a fat emulsion prepared by using glucose is used, fat emulsion having an average particle diameter of <=0.17μm is easily prepared by the effect of the glucose and the vitamin B1 is stabilized.  The glucose is added in a range of 1-8 pts.wt. based on 1 pts.wt. of the fat.
PURPOSE:To provide an agent for lowering the cholesterol level, containing phosphatidylethanolamine as an active component, free of side effects, and effective in a low dose. CONSTITUTION:The objective agent for lowering the cholesterol level is composed of a phospholipid containing >=60% of phosphatidylethanolamine of formula. Phospholipid exsiting in vegetables and animals is effective to lower the cholesterol level in the living body. Within the components of phospholipid, the phosphatidylethanolamine of formula is contained e.g. in egg yolk, fishoil, soybean, etc. Phospholipid containing >=80% of phosphatidylethanolamine can be prepared, e.g. by extracting phospholipid from edd yolk with ethanol, etc., and adding a phospholipase to the obtained phospholipid to substitute the choline segment of phosphatidylcholine with ethanolamine hydrochloride by base exchange reaction.
PROBLEM TO BE SOLVED: To obtain the subject composition that reduces irritation caused by active ingredients, facilitates the production of pharmaceutical preparations, and retains good bioavailability and stability with time by spraying and granulating powder including active ingredients with a binder solution in which a light- weight silicic acid anhydride is dispersed. SOLUTION: Powder including active ingredients (preferably with an average particle size of 1-300 μm) is sprayed with a binder (hydroxypropylcellulose) solution in which a light-weight silicic anhydride (preferably with an average particle size of 0.0001-0.1 μm) is dispersed, and granulated. The active ingredients are the components to be supplied as medicines. Since these ingredients have bitterness and irritation, troubles are caused on the administration, or they melt at a low temperature as their deficient physico-chemical properties and troubles are caused in the production process (for example, in the case of ibuprofen). In a preferred embodiment, the binder solution includes 0.1-10 pts.wt. of the light-weight silicic anhydride per 1 pt.wt. of the hydroxypropylcellulose.
The Moderna cohort is composed of 1000 study participants who will be protected from SARS-CoV-2 infection by Moderna Biotech vaccine. The study participants consist of mildly immunocompromised dialysis patients, severely immunocompromised kidney transplant recipients, and the staff caring for them in the nephrology dispensaries.
Newer agents called sodium glucose co-transporter-2 inhibitors (SGLT2i) have been developed to improve glycemic control and lower hemoglobin A1c by increasing glycosuria. SGLT2i also reduce blood pressure and albuminuria in T2D - possibly through natriuresis. Importantly, a landmark trial "EMPA-REG OUTCOME" demonstrated that the SGLT2i "empagliflozin" is the first anti- hyperglycemic agent to reduce mortality and HF risk, and also to decrease the risk of progressive diabetic nephropathy. Similar benefits were also recently reported in the CANVAS Program trial with canagliflozin. Despite the benefits observed in these two pivotal trials, the mechanisms responsible for beneficial effects of SGLT2i in patients with T2D with respect to the development and/or worsening of HF are not currently known.

In light of the results of EMPA-REG OUTCOME, the investigators aim to elucidate the mechanisms whereby the SGLT2i "ertugliflozin" modifies cardiorenal interactions that regulate fluid volume and neurohormonal activation in patients with T2D and HF (T2D-HF). The investigators will test the hypothesis that ertugliflozin increases proximal tubular natriuresis, thereby reducing plasma volume, without inducing significant renal vasoconstriction or activation of the sympathetic nervous system (SNS) (see below, Figure 1). The systematic understanding of the effects of SGLT2i in the setting of HF will enable the design of rational physiology based strategies to decrease the burden of HF, which could have major clinical and research implications internationally.
NOT FOR INJECTION INTO THE EYE.

Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first dose, have been reported in patients receiving systemic quinolone therapy. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, tingling, pharyngeal or facial edema, dyspnea, urticaria, and itching. Only a few patients had a history of hypersensitivity reactions. Serious anaphylactic reactions require immediate emergency treatment with epinephrine and other resuscitation measures, including oxygen, intravenous fluids, intravenous antihistamines, corticosteroids, pressor amines and airway management, as clinically indicated.

Remove contact lenses before using.
<P>PROBLEM TO BE SOLVED: To provide a bathing agent composition which has remarkable effects such as the improvement of atopic dermatitis symptoms due to the decomposing elimination of chlorine, the maintenance of health by the actions of minus ions, fine radiations, and the like, and the recovery of physical strength after illness.  <P>SOLUTION: This bathing agent composition is characterized by compounding 100 pts. wt. of a mixture of calcined silica with a cerium compound or a cerium-containing mineral with 10 to 30 pts. wt. of ilmenite and 5 to 30 pts. wt. of vitamin C or E.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The present invention discloses a technology for extracting active ingredients of rhubarb, a sanhuang quick release preparation and a preparation method thereof. The present invention overcomes the defects of unstable quality, low biological availability, etc. of the present sanhuang tablets. The present invention is characterized in that the present invention provides two fine extraction technologies for active ingredients of rhubarb, two kinds of novel preparations of sanhuang quick release preparations, and a preparation method for the two kinds of novel preparations. Rhubarb combination anthraquinone and rhubarb free anthraquinone of the active ingredients of the rhubarb of the main medicine of the sanhuang tablets are extracted, and the materials of three kinds of medicines of the sanhuang preparations are all effective parts. The kinds of the auxiliary material of the novel sanhuang preparations are sieved and optimized, a solid dispersed technique is utilized, and the traditional sanhuang tablets are improved to be prepared into sanhuang dispersive tablets, sanhuang capsules and sanhuang drop pills which can quickly release the active ingredients. The novel preparations can be distributed in gstrointestinal tracts in a large area, the absorption points are increased, the leaching of medicines is accelerated, and the biological availability is enhanced.
OC subjects who show high binding to the choroid plexus by a visual analog scale (high, low, and none) will be studied. Subjects with OC will be scanned twice: once with \[18F\]RO-948 and a second scan with \[18F\]AV-1451 in randomized order and within one month of each other.
While smoking prevalence has declined for both men and women over the last two decades, rates among women have shown a much shallower decrease and, in recent years, prevalence of cigarette initiation has been higher for girls than boys. Smoking among women of child-bearing age has significant negative health consequences for mother and child, increasing fetal and infant morbidity and mortality. Women are both less likely to initiate a quit attempt and more likely to relapse if these women do quit. Nicotine replacement therapy (NRT), still the most widely used smoking treatment intervention in the United States, is less effective for women compared with men, and women report less craving reduction on NRT. The endogenous opioid system is involved in smoking initiation, nicotine craving and reward as well as nicotine withdrawal symptoms. Interestingly, research suggests that sexual dimorphic features of the endogenous mu-opioid system may in part explain gender differences in nicotine effects. To better understand the role of the mu-opioid system in poorer NRT responses in women, this proposal will examine NRT effects on mu opioid receptor binding potential (MOR BP) in female compared to male smokers during active versus placebo NRT. Specifically, nicotine dependent women and men in active smoking status will undergo PET imaging for MOR BP measurement using 11C-carfentanil. Following baseline PET measurement in active smoking (scan 1), smokers will be randomized to active or placebo nicotine replacement therapy ((A-NRT or P-NRT); 72 hours later, a second scan will be obtained. As a reference group, demographically-matched women and men who have never smoked will undergo two scans as well. Behavioral measurements of nicotine reward, craving and withdrawal will be obtained repeatedly across the protocol. The proposed research will provide significant new, gender-specific information of scientific and clinical relevance on the function of the mu-opioid system in nicotine dependence and therapeutic effectiveness of nicotine replacement therapy.
<P>PROBLEM TO BE SOLVED: To provide an enhancer for a liquid immune response and to provide a means necessary for development thereof.  <P>SOLUTION: The enhancer for the liquid immune response comprises a substance inhibiting the expression of BANK (B cell scaffold protein with ankyrin repeats). A method for screening a substance positively regulating the liquid immune response comprises evaluating whether or not a test substance inhibits the expression of the BANK and selecting the test substance inhibiting the expression of the BANK as the substance positively regulating the liquid immune response. A BANK-deficient nonhuman animal has an enhanced liquid immune response ability. A BANK-deficient cell has the enhanced liquid immune response ability.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Cereal grains at the milk-ripe stage are harvested, reduced to a paste or pulp, and at least part of the solids, and optionally chlorophyll, are separated therefrom e.g. by centrifuging, expressing, extracting and/or filtering, optionally with the addition of adjuvants, to leave a liquid milky product, referred to as "cereal milk", which has cosmetic uses.  The cereal milk may be fermented with yeast to give an alcoholic product or reacted with lactic acid bacteria to give a lactic acid containing product.  The cereal milk may be concentrated, dried, pasteurized, or preserved by addition of preservatives.  The separated solid residues may be used as forage for cattle.  The fermented or unfermented cereal milk may be sedimented and liquid layers may be removed and processed e.g. concentrated, dried, or pasteurised to yield a cosmetic product.ALSO:Cereal grains at the milk-ripe stage are harvested, reduced to a paste or pulp, and at least part of the solids, and optionally chlorophyll, are separated therefrom e.g. by centrifuging, expressing, extracting and/or filtering, optionally with the addition of adjuvants, to leave a liquid milky product, referred to as "cereal milk", which has cosmetic uses.  The cereal milk may be fermented with yeast to give an alcoholic product or reacted with lactic acid bacteria to give a lactic acid containing product.  The cereal milk may be concentrated, dried, pasteurised, or preserved by addition of preservatives.  The separated solid residues may be used as forage for cattle.  The fermented or unfermented cereal milk may be sedimented and liquid layers may be removed and processed e.g. concentrated, dried or pasteurised to yield a cosmetic product.ALSO:Cosmetic preparations comprise "cereal milk", or an extract or derivative thereof.  Cereal milk is the milky fluid obtained from cereal grains at the milk-ripe stage, and it may be used in the liquid or dry state, fermented or unfermented in creams, lotions, salves, hair treatment liquids and bath additives.
The efficacy of anti-seizure prophylaxis in head injury patients remains controversial. Current recommendations for the use of anti-seizure prophylaxis are based upon a single institution study that has not been reproduced with other studies contradicting their conclusions. The proposed study will be a randomized prospective study at Loyola University Medical Center to assess the efficacy of anti-seizure prophylaxis in patients who have suffered traumatic brain injury (TBI). Patients with suspected TBI will undergo computed tomographic (CT) scan of the head. Following identification of TBI on CT scan, patients will be randomized to one of two study groups. Patients will be randomized to receive a seven-day course of anti-seizure prophylaxis with levetiracetam (UCB Pharma Inc.; Keppra) or randomized to a study group that will not receive anti-seizure prophylaxis. Patients will be consented prior to entry in the study. Patients will be followed for a total of seven days post injury for clinical signs of seizure activity. Additionally, patients will be assessed at one month post injury for clinical signs of seizure activity.